Compare
Vera Therapeutics, Inc. vs Kura Oncology, Inc. vs Arvinas, Inc. vs Maravai Lifesciences Holdings, Inc.
| Latest fiscal year | Vera Therapeutics, Inc. VERA | Kura Oncology, Inc. KURA | Arvinas, Inc. ARVN | Maravai Lifesciences Holdings, Inc. MRVI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $67.48M | $262.60M | $185.74M |
| Revenue growth (YoY) | n/a | +25.2% | -0.3% | -28.3% |
| Gross margin | n/a | n/a | n/a | 18.3% |
| Operating margin | n/a | -449.9% | -45.1% | -115.9% |
| Net margin | n/a | -412.9% | -30.8% | -70.4% |
| Net income | -$299.62M | -$278.67M | -$80.80M | -$130.77M |
| EPS (Diluted) | -$4.66 | -$3.18 | -$1.14 | -$0.90 |
| Operating cash flow | -$241.10M | -$64.06M | -$273.80M | -$57.57M |
| Free cash flow | -$241.73M | -$70.70M | -$275.70M | -$70.72M |
| Cash & equivalents | $354.73M | $149.10M | $142.90M | $216.89M |
| Total assets | $734.73M | $738.36M | $717.90M | $770.58M |
| Total liabilities | $130.21M | $564.23M | $284.00M | $397.87M |
| Shareholders' equity | $604.52M | $174.13M | $433.90M | $212.38M |
| Return on year-end equity | -49.6% | -160.0% | -18.6% | -61.6% |
| Shares outstanding | n/a | 87.86M | 63.50M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Vera Therapeutics, Inc. | Kura Oncology, Inc. | Arvinas, Inc. | Maravai Lifesciences Holdings, Inc. |
|---|---|---|---|---|
| Latest | n/a | $67.48M Ended 2025-12-31 | $262.60M Ended 2025-12-31 | $185.74M Ended 2025-12-31 |
| 1 year earlier | n/a | $53.88M Ended 2024-12-31 | $263.40M Ended 2024-12-31 | $259.19M Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $78.50M Ended 2023-12-31 | $288.94M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $131.40M Ended 2022-12-31 | $883.00M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $53.60M Ended 2021-12-31 | $799.24M Ended 2021-12-31 |